|
Endpoints
|
Recurrent CVEs/Total
|
Crude model
|
Adjusted model
|
|---|
|
HR (95% CI)
|
p value
|
HR (95% CI)
|
p value
|
|---|
|
Composite recurrent CVEs
|
153/2284
| | | | |
|
Lp(a) per-SD increase
| |
1.007 (1.002–1.013)
|
0.007
|
1.008 (1.002–1.014)
|
0.006
|
|
Lp(a) < 10
|
37/846
|
Reference
| |
Reference
| |
|
10 ≤ Lp(a) < 30
|
59/769
|
1.736 (1.151–2.619)
|
0.009
|
1.720 (1.099–2.692)
|
0.018
|
|
Lp(a) ≥ 30
|
57/669
|
1.960 (1.296–2.965)
|
0.001
|
2.049 (1.308–3.212)
|
0.002
|
|
Non-fatal MI
|
30/2284
| | | | |
|
Lp(a) per-SD increase
| |
1.012 (1.001–1.023)
|
0.039
|
1.012 (1.000–1.024)
|
0.050
|
|
Lp(a) < 10
|
7/846
|
Reference
| |
Reference
| |
|
10 ≤ Lp(a) < 30
|
8/769
|
1.259 (0.457–3.472)
|
0.656
|
1.539 (0.529–4.474)
|
0.428
|
|
Lp(a) ≥ 30
|
15/669
|
2.737 (1.116–6.714)
|
0.028
|
3.016 (1.144–7.949)
|
0.026
|
|
Stroke
|
55/2284
| | | | |
|
Lp(a) per-SD increase
| |
1.002 (0.992–1.011)
|
0.761
|
1.001 (0.990–1.012)
|
0.815
|
|
Lp(a) < 10
|
17/846
|
Reference
| |
Reference
| |
|
10 ≤ Lp(a) < 30
|
22/769
|
1.408 (0.748–2.651)
|
0.289
|
1.355 (0.674–2.724)
|
0.394
|
|
Lp(a) ≥ 30
|
16/669
|
1.199 (0.606–2.372)
|
0.603
|
1.118 (0.518–2.413)
|
0.777
|
|
CVD deaths
|
68/2284
| | | | |
|
Lp(a) per-SD increase
| |
1.009 (1.002–1.017)
|
0.019
|
1.011 (1.003–1.020)
|
0.011
|
|
Lp(a) < 10
|
13/846
|
Reference
| |
Reference
| |
|
10 ≤ Lp(a) < 30
|
29/769
|
2.419 (1.257–4.652)
|
0.008
|
2.242 (1.108–4.535)
|
0.025
|
|
Lp(a) ≥ 30
|
26/669
|
2.539 (1.305–4.942)
|
0.006
|
2.708 (1.340–5.475)
|
0.006
|
- The adjusted model including age, sex, body mass index, current smoking, hypertension, dyslipidemia, family history of coronary artery disease, diseased vessels, low-density lipoprotein cholesterol, fasting blood glucose, statin and anti-diabetes drugs use
- CVEs cardiovascular events, MI myocardial infarction, CVD cardiovascular disease
